Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Lew

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Clinical Parkinsonism & Related Disorders|August 29, 2022
Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?Stuart H Isaacson, Fernando L Pagan, Mark F Lew, et al.
Current Medical Research and Opinion|April 5, 2007
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's diseaseMark F Lew, Rajesh Pahwa, Maureen Leehey, et al.
Clinical Neuropharmacology|August 31, 2012
Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trialsRobert B Chinnapongse, Mark F Lew, Joaquim J Ferreira, et al.
The International Journal of Neuroscience|January 19, 2018
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaMark F Lew, Allison Brashear, Khashayar Dashtipour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2008
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseRobert A Hauser, Mark F Lew, Howard I Hurtig, et al.
The International Journal of Neuroscience|May 28, 2010
Long-term efficacy of rasagiline in early Parkinson's diseaseMark F Lew, Robert A Hauser, Howard I Hurtig, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Independent Associations of Sleep and Walking with Cognition in Parkinson's Disease: A Perivascular Spaces AnalysisFrancesca Sibilia, Giuseppe Barisano, Maryam Fotouhi, et al.
Plos One|February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Biomarkers in Medicine|September 26, 2019
Levels of oligomeric α-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controlsSarah F Hamm-Alvarez, Srikanth R Janga, Maria C Edman, et al.
Plos One|April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Clinical Parkinsonism & Related Disorders|August 29, 2022
Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?Stuart H Isaacson, Fernando L Pagan, Mark F Lew, et al.
Current Medical Research and Opinion|April 5, 2007
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's diseaseMark F Lew, Rajesh Pahwa, Maureen Leehey, et al.
Clinical Neuropharmacology|August 31, 2012
Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trialsRobert B Chinnapongse, Mark F Lew, Joaquim J Ferreira, et al.
The International Journal of Neuroscience|January 19, 2018
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaMark F Lew, Allison Brashear, Khashayar Dashtipour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 17, 2008
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's diseaseRobert A Hauser, Mark F Lew, Howard I Hurtig, et al.
The International Journal of Neuroscience|May 28, 2010
Long-term efficacy of rasagiline in early Parkinson's diseaseMark F Lew, Robert A Hauser, Howard I Hurtig, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Independent Associations of Sleep and Walking with Cognition in Parkinson's Disease: A Perivascular Spaces AnalysisFrancesca Sibilia, Giuseppe Barisano, Maryam Fotouhi, et al.
Plos One|February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Biomarkers in Medicine|September 26, 2019
Levels of oligomeric α-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controlsSarah F Hamm-Alvarez, Srikanth R Janga, Maria C Edman, et al.
Plos One|April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b studyAtul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Pageof 5